The pursuit of market outperformance leads investors to the practice of hand-picking stocks. Skillful choices can be a catalyst for significant wealth enhancement.
As of close of business last night, Globus Medical Inc’s stock clocked out at $58.89, down -0.54% from its previous closing price of $59.21. In other words, the price has decreased by -$0.54 from its previous closing price. On the day, 1.11 million shares were traded.
Ratios:
To gain a deeper understanding of GMED’s stock, we examine its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 17.28 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 15.26. For the most recent quarter (mrq), Quick Ratio is recorded 2.72 and its Current Ratio is at 4.45. In the meantime, Its Debt-to-Equity ratio is 0.02 whereas as Long-Term Debt/Eq ratio is at 0.02.
On January 10, 2025, BofA Securities Upgraded its rating to Neutral which previously was Underperform but kept the price unchanged to $97.
Morgan Stanley Upgraded its Equal-Weight to Overweight on December 02, 2024, whereas the target price for the stock was revised from $83 to $100.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Feb 28 ’25 when RHOADS ANN D sold 7,500 shares for $78.68 per share. The transaction valued at 590,100 led to the insider holds 35,384 shares of the business.
RHOADS ANN D bought 7,500 shares of GMED for $590,000 on Feb 28 ’25. On Jan 10 ’25, another insider, Pfeil Keith W, who serves as the COO, CFO of the company, sold 14,167 shares for $88.29 each. As a result, the insider received 1,250,770 and left with 0 shares of the company.
Valuation Measures:
As of this moment, Globus’s Price-to-Earnings (P/E) ratio for their current fiscal year is 44.05, and their Forward P/E ratio for the next fiscal year is 15.87. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 4.44. For the stock, the TTM Price-to-Sale (P/S) ratio is 3.18 while its Price-to-Book (P/B) ratio in mrq is 1.95.
Stock Price History:
Over the past 52 weeks, GMED has reached a high of $94.93, while it has fallen to a 52-week low of $54.48. The 50-Day Moving Average of the stock is -14.18%, while the 200-Day Moving Average is calculated to be -22.68%.
Shares Statistics:
A total of 112.93M shares are outstanding, with a floating share count of 112.16M. Insiders hold about 17.15% of the company’s shares, while institutions hold 82.32% stake in the company.
Earnings Estimates
The stock of Globus Medical Inc (GMED) is currently in the spotlight, with 14.0 analysts actively rating and assessing its market standing.The consensus estimate for the next quarter is $0.8, with high estimates of $0.86 and low estimates of $0.74.
Analysts are recommending an EPS of between $3.36 and $3.03 for the fiscal current year, implying an average EPS of $3.17. EPS for the following year is $3.71, with 14.0 analysts recommending between $4.03 and $3.43.
Revenue Estimates
In the current quarter, 12 analysts expect revenue to total $738.91M. It ranges from a high estimate of $763.6M to a low estimate of $717.9M. As of the current estimate, Globus Medical Inc’s year-ago sales were $629.69MFor the next quarter, 12 analysts are estimating revenue of $734.81M. There is a high estimate of $747M for the next quarter, whereas the lowest estimate is $724.1M.
A total of 13 analysts have provided revenue estimates for GMED’s current fiscal year. The highest revenue estimate was $2.9B, while the lowest revenue estimate was $2.79B, resulting in an average revenue estimate of $2.85B. In the same quarter a year ago, actual revenue was $2.52BBased on 13 analysts’ estimates, the company’s revenue will be $3.1B in the next fiscal year. The high estimate is $3.23B and the low estimate is $3B.
